Official Title
Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia
Brief Summary

Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions. Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function. Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.

Detailed Description

Objective is to evaluate prevalence of long-term respiratory complications after severe
SARS-CoV2 pneumonia.

Unknown status
Severe SARS-CoV2 Pneumonia

Other: Blood sample and data record

Blood sample and data record

Eligibility Criteria

Inclusion Criteria:

- Adult patient

- Patient with with severe SARS-CoV2 pneumonia

- Patient consenting to participate to the study

- Patient enrolled in the national healthcare insurance program

Exclusion Criteria:

- Patient under 18 years

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Damien JOLLY
Reims, France

Investigator: Jeanne-Marie PEROTIN-COLLARD
Contact: 03 10 73 67 63
jmperotin-collard@chu-reims.fr

Contacts

Jeanne-Marie PEROTIN-COLLARD
03 10 73 67 63
jmperotin-collard@chu-reims.fr

NCT Number
Keywords
SARS-CoV2
long term
complication
Pneumonia
MeSH Terms
Pneumonia